title: Involvement of platelet-activating factor in zymosan-induced rat pleurisy.
abstract: The role of platelet-activating factor (PAF) in inflammatory reactions was studied in zymosan-induced rat pleurisy. Pleurisy was induced by injection of a 2% zymosan suspension into the pleural cavity of rats. The time course of pleural exudate accumulation, the exudation rate, and exudate leukocyte numbers were followed then for 96 hr. Peak pleural exudate accumulation was about 3 mL at 24 hr, whereas the exudation rate increased biphasically with peaks at 0.5 hr and 5 hr. The migration of leukocytes into the pleural cavity increased with time up to 48 hr. The polymorphonuclear leukocytes were the dominant white cells in the exudate between 5 and 16 hr, but mononuclear leukocytes started to outnumber them around 24 hr. Pretreatment with cyproheptadine (5 mg/kg), an inhibitor of both histamine and serotonin, significantly suppressed pleural fluid accumulation and the exudation rate at 0.5 hr. The PAF antagonist CV-6209 (1 mg/kg) significantly suppressed pleural fluid accumulation and the exudation rate at both 0.5 and 5 hr. At either time point, the parameters were not suppressed by indomethacin. We detected PAF activity in the high-performance liquid chromatography (HPLC) fraction (with a retention time corresponding to that of authentic PAF) of the exudates at 0.5 hr, 5 hr, and 16 hr using an aggregation bioassay with washed rabbit platelets. The results suggest that in zymosan-induced rat pleurisy, histamine and/or serotonin are the main mediators of exudation at 0.5 hr and that PAF may be partly responsible for exudation at 0.5 hr and later at 5 hr to 16 hr.
authors.affiliation: Department of Pharmacology, School of Pharmaceutical Sciences, Kitasato University, Tokyo, Japan.
authors.forename: Y
authors.initials: Y
authors.lastname: Imai
authors.forename: M
authors.initials: M
authors.lastname: Hayashi
authors.forename: S
authors.initials: S
authors.lastname: Oh-ishi
mesh_terms: D000818:Animals; D003533:Cyproheptadine / Q000627:therapeutic use*; D004804:Eosinophils / Q000502:physiology; D007249:Inflammation; D007962:Leukocytes / Q000187:drug effects / Q000502:physiology*; D008297:Male; D008407:Mast Cells / Q000502:physiology; D009504:Neutrophils / Q000502:physiology; D010972:Platelet Activating Factor / Q000031:analogs & derivatives / Q000037:antagonists & inhibitors / Q000302:isolation & purification / Q000502:physiology*; D010998:Pleurisy / Q000139:chemically induced / Q000503:physiopathology*; D011726:Pyridinium Compounds / Q000627:therapeutic use*; D011817:Rabbits; D051381:Rats; D011919:Rats, Inbred Strains; D015054:Zymosan
chemical_list: D010972:Platelet Activating Factor; D011726:Pyridinium Compounds; C053321:CV 6209; D003533:Cyproheptadine; C037145:1-hexadecyl-2-acetyl-glycero-3-phosphocholine; D015054:Zymosan